BIO-key Q3: $4.01/Share Loss, Going-Concern Warning, Ineffective Controls
BKYI sits 37% above its 52-week low of $1.55.
Summary
BIO-key reported a Q3 net loss of $886,083 ($4.01 per share after a $4.5M non-cash warrant-inducement dividend) on $1.48M revenue, and disclosed substantial doubt about its ability to continue as a going concern with only $2.22M of cash.
Key Events · Earnings and Guidance · BKYI
-
Going-Concern Warning Disclosed
Management states the Company does not have enough cash for twelve months of operations and will need additional third-party financing; the financials carry no adjustments for recoverability if it cannot continue.
-
Q3 Loss Narrowed on Flat Revenue
Net loss was $886,083 versus $964,849 a year earlier; revenue was $1,482,781 versus $1,549,706, with license fees up 39% to $1,275,249 offsetting a 97% drop in hardware to $12,404.
-
$4.5M Non-Cash Warrant Dividend
The August 10, 2026 warrant inducement produced a deemed dividend of $4,502,004, pushing net loss available to common stockholders to $5,388,087, or $4.01 per share.
-
Cash Down to $2.2M
Cash and equivalents were $2,219,428 at September 30, 2026 versus $2,694,663 at December 31, 2025, against roughly $750,000 per month of required operating spend.
Analysis · BKYI · Technology
The Q3 10-Q carries an explicit going-concern warning: management states it does not have enough cash for twelve months of operations and will need third-party financing. With cash down to $2.22M from $2.69M at year-end and roughly $750,000 of monthly operating spend, runway is measured in months, not years. Most of the headline $4.01 per-share loss is accounting — a $4.5M non-cash deemed dividend from the August warrant inducement — while the underlying net loss actually narrowed to $886,083 from $964,849. Revenue was roughly flat at $1.48M as license growth (+39%) offset a 97% collapse in hardware sales. On top of the liquidity problem, management concluded disclosure controls were ineffective — a governance flag.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BKYI was trading at $2.13 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $1.55 to $11.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.